Shape the future of consumer health.
Rx to OTC switch remains one of the most strategically important growth levers in consumer health—but the rules of engagement are evolving. As consumer self care behaviours accelerate and healthcare system pressures intensify, the FDA’s Additional Condition for Nonprescription Use (ACNU) framework is redefining how prescription products can transition to OTC access.
In this on demand webinar, IQVIA Consumer Health and industry experts from Idea Evolver explore how ACNU is reshaping Rx to OTC regulatory strategy in the United States—enabling more ambitious switch candidates, expanding consumer access, and setting new expectations for evidence generation, digital enablement, and commercial execution. Discover how leading organisations are navigating this new switch environment to unlock sustainable growth and maximise the value of their portfolios.
Key discussions you won’t want to miss:
- How to unlock scalable growth with next generation Rx to OTC switch
shifting from one off transitions to sustainable, behaviour driven access models - Why ACNU opens new pathways for more ambitious switch candidates
enabling access where traditional labelling alone would not be sufficient - What landmark U.S. switches reveal about accelerating access
and how evolving FDA thinking is creating new commercial opportunities - How to build the evidence regulators require
demonstrating safe, effective use through real world consumer behaviour and robust data - How digital tools and AI enable safe, scalable consumer access
supporting self selection, adherence, and engagement in real world settings
Entering a New RX to OTC Switch Era
in the United States
See key webinar timecodes below:
- 05:56 — The evolving Rx‑to‑OTC switch landscape
Why switch is shifting from convenience to a strategic, behaviour‑driven growth lever - 09:55 — Landmark U.S. switches and what they signal
What naloxone and oral contraception approvals reveal about FDA priorities and access - 12:20 — Introducing ACNU: a new regulatory pathway
How additional conditions are expanding what’s possible for OTC access - 17:13 — How ACNU is reshaping the switch model
Moving beyond labelling alone to real‑world delivery and execution - 24:10 — The behavioural evidence regulators expect
The critical questions sponsors must answer to demonstrate safe use - 29:03 — ACNU in practice: the role of digital and software
Why intuitive consumer journeys rely on robust, highly controlled systems - 37:28 — Identifying high‑potential switch opportunities
Where future ACNU‑enabled growth is most likely to emerge - 46:30 — Key takeaways for sponsors
What this new switch era means for strategy, capability, and execution
Ready to accelerate Rx‑to‑OTC switch success in the U.S.?
Connect with our experts to understand how ACNU can unlock new regulatory pathways, expand access, and drive growth.
Delivering a successful Rx to OTC switch requires an integrated approach across regulatory strategy, evidence generation, and real world implementation. Explore how IQVIA supports programmes end to end—from concept and study design through to approval—combining real world evidence, digital health solutions, and global expertise to drive successful outcomes.
Related solutions
Compelling claims to capture the minds of consumers
Navigate regulatory pathways with confidence
